Light and Exercise in Night-shift Workers

This study is not yet open for participant recruitment.
Verified January 2013 by Universitätsklinikum Hamburg-Eppendorf
Sponsor:
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier:
NCT01767181
First received: January 10, 2013
Last updated: January 11, 2013
Last verified: January 2013

January 10, 2013
January 11, 2013
February 2013
December 2013   (final data collection date for primary outcome measure)
Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
The difference of the expression pattern of the CLOCK gene in peripheral blood mononuclear cells (PBMCs) after 12 weeks between intervention and control group
Same as current
Complete list of historical versions of study NCT01767181 on ClinicalTrials.gov Archive Site
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The changes in body weight, BMI, abdominal circumference from baseline to 12 weeks of intervention
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The differences in the circadian expression pattern of genes involved in circadian rhythm (e.g., Cryptochrome 1, Bmal 1, RORα, Rev-erbα, Period 1, Period 3, Timeless, Adam 17, PPAR-α, PPAR-γ, Klotho, DDAH-1, DDAH-2, AGXT 2, AGAT, VDR, TIMP 3) in peripheral blood mononuclear cells (PBMCs) after 12 weeks between intervention and control group
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The differences in the expression of genes involved in circadian rhythm (e.g. Cryptochrome 1, Clock, Bmal 1, RORα, Rev-erbα, Period 1, Period 3, Timeless, Adam 17, PPAR-α, PPAR-γ, Klotho, DDAH-1, DDAH-2, AGXT 2, AGAT, VDR, TIMP 3) in adipose tissue and muscle tissue, between baseline and 12 weeks of intervention (restricted to participants who consent to this part of the study
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The reversibility of the differences in the expression profiles of genes involved in circadian rhythm in peripheral blood mononuclear cells (PBMCs) 12 weeks after the end of the intervention period (=week 24 of the study)
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The differences in epigenetic profiles of genes involved in circadian rhythm between baseline and 12 weeks of intervention
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The reversibility of the differences in the biochemical markers and indices of cardiometabolic function (e.g. fasting glucose, fasting insulin, HOMA, OGTT, QUICKI index, Stumvoll-ISI index, HbA1c, ADMA, SDMA, fibrinogen, PAI-1, triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, C-reactive protein, C3, systolic and diastolic blood pressure, endothelial function, IMT) 12 weeks after the end of the intervention period (=week 24 of the study)
  • Efficacy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The differences in metabolomic profiling between baseline, 12 weeks of intervention, and after 12 weeks of wash-out (Plasma samples will be collected for metabolomic analysis at these time points)
Same as current
Not Provided
Not Provided
 
Light and Exercise in Night-shift Workers
Effects of Timed Intensive Light Therapy or Timed Physical Exercise on Markers of Central and Peripheral Circadian Rhythm and on Cardiometabolic Function in Night Shift Workers

EuRhythDia is a multicenter, controlled and randomized study. The aim of the study is to investigate the effects of 12 weeks of randomized timed light therapy or timed physical exercise as a chronotherapeutic lifestyle intervention on markers of central and peripheral circadian rhythms and cardiometabolic function in healthy night shift workers.

Lifestyle interventions have been recognized as important means to prevent and treat cardiometabolic disease. However, compliance of the European population to general recommendations of exercise and weight loss is unsatisfactory. There have been no studies that have attempted to convert the exciting new experimental data on the circadian clock, lifestyle, and cardiometabolic risk into diagnostic tools or novel therapeutic approaches via structured multidisciplinary efforts. One of the aims of the EuRhytDia study is to study novel applications of established lifestyle interventions by co-ordinating the timing of interventions with circadian rhythmicity.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy Night Shift Workers
  • Other: Intensive light therapy
    Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
  • Other: Exercise
    Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
  • No Intervention: A
    Control group without intervention
  • Experimental: B
    Intensive light therapy during the first half of the night shift
    Intervention: Other: Intensive light therapy
  • Experimental: C
    Exercise before the beginning of the night shift
    Intervention: Other: Exercise
  • Experimental: D
    Exercise after the end of the night shift
    Intervention: Other: Exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
216
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female subjects above the age of 18
  • Night shift workers on regular night shifts with at least 3 nights in a row per month during the study period
  • Subjects must have been on night shifts for at least 4 weeks before inclusion into the study
  • Signed written informed consent

Exclusion Criteria:

  • Regular use of drugs (prescription or non-prescription, exception: contraceptives) or dietary supplements within 4 weeks before inclusion of the study
  • Pregnancy or breast feeding
  • Any severe somatic or psychic disease (malignant or non-malignant
  • Any known ophthalmological condition that prevents the exposure to bright light (e.g. cataract, glaucoma, retinopathy, macular degeneration, acute eye infections, lesions of the cornea)
  • Any skin condition or use of drugs associated with increased photosensitivity;
  • Any kind of disability that would prevent the subjects from participation in exercise training sessions
Both
18 Years and older
Yes
Not Provided
Not Provided
 
NCT01767181
EuRhythDia-1
No
Universitätsklinikum Hamburg-Eppendorf
Universitätsklinikum Hamburg-Eppendorf
Not Provided
Principal Investigator: Rainer Böger, MD Universitätsklinikum Hamburg-Eppendorf
Universitätsklinikum Hamburg-Eppendorf
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP